A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Status:
Active, not recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults
with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite
standard of care, which includes treatment with angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers (ARBs). These patients are at high risk for
progression of kidney disease, which can result in end-stage renal failure.